Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

FDA Perspective: Reducing Cost, Increasing Access to Cancer Care

TOP - February 2019, Vol 12, No 1 - Health Policy
Chase Doyle

In a time when the country feels more politically divided than ever, there is broad consensus that Medicare should be allowed to negotiate prescription drug prices directly with drug makers, and that the FDA should expedite approvals of generic cancer drugs to lower patients’ out-of-pocket costs.

At the 2018 Palliative and Supportive Care in Oncology Symposium, Tatiana M. Prowell, MD, Breast Cancer Scientific Liaison at the FDA, and Assistant Professor of Oncology, Johns Hopkins University, discussed ways in which the FDA can help ease the financial burden on patients with cancer while improving access to clinical trials.

“Our system is broken,” said Dr Prowell. “It’s not really designed for the disease that we treat, and the kind of drugs that we prescribe, so it’s necessary to explore alternative payment models.”

Disparity in Drug Costs

Despite being the largest drug purchaser in the world, Medicare is prohibited by law from negotiating prices for Medicare Part B drugs, which provides a potential financial incentive for providers to prescribe high-cost drugs. To discourage price inflation, the current federal government has proposed the International Pricing Index model to base drug payment levels on international prices of the same drug, to be phased in over 5 years. According to the Centers for Medicare & Medicaid Services, this should reduce costs for Medicare beneficiaries, by increasing adherence and access to prescription drugs, as well as introducing competition into the system of paying for physician-administered drugs by bringing in private sector vendors.

“The administration’s goal, to a large degree, is to address this disparity in drug pricing between the United States and the rest of the world,” said Dr Prowell. “The narrative is that we are subsidizing drug development and innovation for the rest of the world, and many view this as unfair,” she added.

“Although it’s not a perfect solution, this model could potentially reduce costs to the American taxpayer,” Dr Prowell said.

According to Dr Prowell, the FDA has been exploring ways to bring generic drugs to market faster. By offering expedited review of the first 3 generic drug applications, for example, the FDA is trying to ensure the availability of at least 2 competitors and, ideally, a third, in case one company stops manufacturing the drug.

“We’ve reduced review times for generics by more than 50%, while addressing some loopholes for impeding introduction of generics and biosimilars,” Dr Prowell said. “Unfortunately, the majority of drugs that we’re treating patients with these days in oncology are not drugs that have generics available. These are drugs that are still on patent, or are still under periods of exclusivity.”

Improving Access to Care

Another priority is better patient access to care. Concerns about missed work and lost wages may be prohibiting some patients from participating in clinical trials, according to Dr Prowell. Although the Affordable Care Act mandates that most private insurers cover routine costs of care, said Dr Prowell, it does not require coverage of clinical trials if they are out of network, which is a problem for patients who have limited network options.

“Coverage of complications is less well-defined and exposes patients to a lot of risk, which is a huge barrier to patients going on clinical trials,” Dr Prowell said. “Patients are nervous about what happens if they get a complication…and their insurance refuses to cover.”

Potential Solutions

What regulators can fix most readily, according to Dr Prowell, are the substantial ancillary costs of clinical trials, such as travel, lodging, childcare, and lost wages.

“Medicaid still has no federal mandates for trial coverage, and this is a place where I think there really needs to be advocacy,” said Dr Prowell, adding that patient advocates are also encouraging companies to conduct clinical trials in underserved areas. The FDA is currently investigating opportunities to decentralize clinical trials to address disparities in trial participation.

“The notion that patients all have to come in a central fashion to have their blood drawn, or get their scans done, is false,” said Dr Prowell. “We are also looking at ways in which telemedicine and wearable devices can help us capture patient history and vital signs.”

Related Items
Overcoming Current Barriers to the Use of CAR T-Cell Therapy in the Community Setting
Chase Doyle
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Immunotherapy
Oncology Reimbursement Reform: Changes on the Horizon
Chase Doyle
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
CAR T-Cell Therapy Targeting Solid Tumors
Chase Doyle
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Immunotherapy
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA
Discussing Costs with Your Patient Can Reduce Financial Toxicity
Chase Doyle
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Best Practices
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Pancreatic Cancer
FDA Taking Steps to Promote Generic Drug Competition and Improve Patient Access to Therapies
Eileen Koutnik-Fotopoulos
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Health Policy
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
Web Exclusives published on April 9, 2018 in Leukemia
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
Web Exclusives published on April 9, 2018 in Immunotherapy
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Last modified: June 4, 2019